GlucoTrack, Inc. (NASDAQ:GCTK) Director Drew Sycoff Buys 182,540 Shares

GlucoTrack, Inc. (NASDAQ:GCTK) Director Drew Sycoff purchased 182,540 shares of the firm’s stock in a transaction that occurred on Monday, April 22nd. The stock was acquired at an average price of $1.26 per share, for a total transaction of $230,000.40. Following the completion of the purchase, the director now owns 2,951,258 shares of the company’s stock, valued at $3,718,585.08. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

GlucoTrack Price Performance

Shares of GlucoTrack stock traded down $0.28 during trading on Wednesday, reaching $0.48. The company’s stock had a trading volume of 1,584,982 shares, compared to its average volume of 182,400. The company has a quick ratio of 3.22, a current ratio of 3.22 and a debt-to-equity ratio of 0.06. GlucoTrack, Inc. has a 12-month low of $0.13 and a 12-month high of $1.00. The company has a market capitalization of $12.82 million, a P/E ratio of -1.29 and a beta of 0.29. The business has a 50 day moving average price of $0.38 and a 200-day moving average price of $0.28.

GlucoTrack (NASDAQ:GCTK) last posted its earnings results on Thursday, March 28th. The company reported ($0.10) EPS for the quarter.

GlucoTrack Company Profile

GlucoTrack, Inc, a medical device company, focuses on designing, developing, and commercializing non-invasive glucose monitoring devices for use by people with diabetes in the United States. It develops GlucoTrack, a non-invasive blood glucose monitor that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain.